<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03095040</url>
  </required_header>
  <id_info>
    <org_study_id>CM082-CA-Ⅱ-201</org_study_id>
    <nct_id>NCT03095040</nct_id>
  </id_info>
  <brief_title>CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma</brief_title>
  <official_title>The Efficacy and Safety of CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma: a Randomized, Double-blind, Double Dummy, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnewPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AnewPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double blind, phase 2/3 study is aimed to evaluate the efficacy and safety&#xD;
      of CM082 in combination with everolimus in Chinese patients with advanced renal cell&#xD;
      carcinoma. The primary endpoint is progression-free survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 16, 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>The internal between the date of randomization and the date of disease progression, unaccepted toxicity, or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>The internal between the date of randomization and the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>The percentage of patients with tumor response in overall population</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Renal Cell Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>CM082 combined with everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CM082</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CM082 combined with everolimus</intervention_name>
    <description>CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles</description>
    <arm_group_label>CM082 combined with everolimus</arm_group_label>
    <other_name>X-82</other_name>
    <other_name>Affinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CM082</intervention_name>
    <description>CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for everolimus (2 tablets) taken orally once a day on 28-day cycles</description>
    <arm_group_label>CM082</arm_group_label>
    <other_name>X-82</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for CM082 (2 tablets) taken orally once a day on 28-day cycles</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Affinitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of clear cell renal cell carcinoma&#xD;
&#xD;
          -  Progressed on at least one standard therapy with VEGFR TKI&#xD;
&#xD;
          -  Measurable disease per Recist v1.1&#xD;
&#xD;
          -  Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Adequate organ functions, and meet the following requirements:&#xD;
&#xD;
        Bone marrow: ANC ≥1.5*109/L (1500/mm3), platelet ≥100*109/L, and hemoglobin ≥9 g/dL Liver:&#xD;
        Total bilirubin ≤1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT)&#xD;
        and aspartate aminotransferase (AST) ≤1.5x the upper limit of normal (ULN) if no liver&#xD;
        involvement or ≤5x the upper limit of normal with liver involvement Kidney: Creatinine ≤&#xD;
        1.25 x ULN, urine protein &lt;1+ Heart: LVEF ≥ 50%&#xD;
&#xD;
          -  Willingness and ability to comply with trial and follow-up procedures&#xD;
&#xD;
          -  Ability to understand the nature of this trial and give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving anti-cancer treatment; currently or previously have received 2 or&#xD;
             more systemic anti-cancer treatment&#xD;
&#xD;
          -  Other tumors in addition to renal cell carcinoma&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Known hypersensitivities to CM082 or everolimus&#xD;
&#xD;
          -  Those with concurrent condition(e.g. psychological, neuronal, cardiovascular,&#xD;
             respiratory conditions or infections) that in the investigator's opinion would&#xD;
             jeopardize compliance with the protocol&#xD;
&#xD;
          -  Patients with known central nervous system (CNS) metastases&#xD;
&#xD;
          -  Presence of active gastrointestinal (GI) disease or other condition that will&#xD;
             interfere significantly with the absorption, distribution, metabolism, or excretion of&#xD;
             CM082 or everolimus&#xD;
&#xD;
          -  Any active infection&#xD;
&#xD;
          -  Drug or alcohol abuser&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Guo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Vorolanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

